Publication: Modelado del tratamiento de problemas de próstata con terapias hormonales
Loading...
Official URL
Full text at PDC
Publication Date
2021-09-02
Authors
Advisors (or tutors)
Editors
Journal Title
Journal ISSN
Volume Title
Publisher
Citations
Exportar
Abstract
El cáncer de próstata es una enfermedad que en el 2030 podría llegar a afectar a 1.7 millones de personas pudiendo ocasionar alrededor de 500.000 muertes al año en los países desarrollados [Ignacio et al., 2012], por tanto el estudio de la mejora de los tratamientos debe ser una prioridad. En este trabajo se estudia un modelo de ecuaciones diferenciales que tiene como objetivo optimizar la aplicación de terapias de supresión intermitente de los andrógenos a través de una medición de los niveles del antígeno prostático específico. A través de este modelo se consigue clasificar a los pacientes de cáncer de próstata en función de su sensibilidad al tratamiento y de esta manera mejorar la eficacia de la terapia y mejorar su calidad de vida.
Prostate cancer is a disease that could affect 1.7 million people and could cause around 500,000 deaths per year in developed countries by 2030 [Ignacio et al., 2012], therefore the study of improved treatments should be a priority. This paper studies a differential equation model that aims to optimise the application of intermittent androgen suppression therapies by measuring prostatespecic antigen levels. Through this model it is possible to classify prostate cancer patients according to their sensitivity to treatment and thus improve the efficacy of therapy and improve their quality of life.
Prostate cancer is a disease that could affect 1.7 million people and could cause around 500,000 deaths per year in developed countries by 2030 [Ignacio et al., 2012], therefore the study of improved treatments should be a priority. This paper studies a differential equation model that aims to optimise the application of intermittent androgen suppression therapies by measuring prostatespecic antigen levels. Through this model it is possible to classify prostate cancer patients according to their sensitivity to treatment and thus improve the efficacy of therapy and improve their quality of life.